// STATE LEGISLATION TRACKER

Kentucky SB 164: AN ACT relating to cannabis.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: In committee

State: Kentucky
Bill: SB 164
Session: 2026RS
Filed: 2026-02-05
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Kentucky SB164 is a cannabis bill focused on decriminalizing personal-use possession, conforming related criminal laws, exempting certain cannabis accessories and quantities from penalties or taxes, and allowing some cannabis conviction expungements. Based on the available title, subjects, summary, and status, it does not appear to regulate peptides, compounded medications, prescribers, telehealth, FDA 503A/503B compounding, or PDMP rules.

Key Points

No apparent change to compounded peptide access
No apparent change to off-label prescribing rules
No apparent change to NP or naturopathic scope
No apparent change to telehealth prescribing
No apparent FDA 503A or 503B compounding impact

What to Watch For

Note Bill appears limited to cannabis and related criminal penalties, not peptide prescribing or compounding.

Note Because it amends drug-law sections, monitor for amendments that could touch controlled-substance or PDMP rules.

Note Expungement provisions may matter to cannabis users, but not directly to peptide patients or clinicians.

Where the Bill Stands

SB164 was introduced and referred to the Senate Committee on Committees on February 5, 2026.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws